MCP简体中文Upgrade
Market/Categories/Business Specialist/RetinAI Discovery

Independent product intelligence · Worldwide · 2026-05-01 → 2026-07-31

RetinAI Discoveryretinai.com

RetinAI Discovery is an AI-powered healthcare platform that enables medical professionals and pharmaceutical companies to manage clinical data, obtain AI-driven insights, and optimize clinical and research workflows in ophthalmology.

Business Specialistretinai.comTracked since 2026-08-211 discovery source
1.4KBacklinks
325Referring domains
21Domain authority
-3.3%Referring domains · 90 days

Authority & distribution

How strong is RetinAI Discovery’s web footprint?

Backlinks measure accumulated distribution; referring domains show how broadly that authority is spread. Both are observable on the open web, so both are published for every product here.

Backlinks

1.4KCurrent snapshot

Referring domains

325Current snapshot

Authority

21Domain authority · category median 22

90-day move

-3.3%Referring domains, last 90 days
At 21, RetinAI Discovery sits below the 22 median for its category.

Trajectory · Pro

The counts above are the latest of 370 daily observations. The curve through them is on the full profile.

See the trajectoryOpen the full profile

Traffic & engagement

Where RetinAI Discovery ranks

Measured · Pro

Measured for this product: global rank, country rank and category rank.

Unlock this profileOpen the full profile

AI referral visibility

Which AI assistants are already sending RetinAI Discovery traffic?

Measured · Pro

Measured for this product: AI referral traffic.

Unlock this profileOpen the full profile

Product profile

What RetinAI Discovery is selling.

Traffic makes more sense when you can connect it to the actual product promise.

“RetinAI Discovery”

RetinAI Discovery is an AI-powered healthcare platform that enables medical professionals and pharmaceutical companies to manage clinical data, obtain AI-driven insights, and optimize clinical and research workflows in ophthalmology.

Business SpecialistSeen 2026-08-21 → 2026-08-21Coverage tier C

What we have measured

4 of 8 signal groups are available for this product: identity, authority and backlinks, AI referrals, search demand.

Not measured for this domain: traffic and engagement, audience demographics, country distribution, acquisition mix. Those sections are left out of the page rather than filled with estimates.

Canonical website: https://www.retinai.com

Observed across 1 discovery source.

Research questions

What the evidence answers about RetinAI Discovery.

Every answer is tied to a source we collected, and the questions with no evidence behind them are left unanswered rather than guessed.

What problem does RetinAI Discovery solve?

RetinAI Discovery is an AI-powered healthcare platform that enables medical professionals and pharmaceutical companies to manage clinical data and obtain AI-driven insights to optimize clinical and research workflows in ophthalmology. It is designed to accelerate and improve ROI from R&D to commercialization. The platform is used for data collection, processing, visualization, and global collaboration to extract insights about disease progression and treatment outcomes.

What does RetinAI Discovery offer in terms of features, surfaces, or integrations?

RetinAI Discovery offers a data platform for managing and accessing data from anywhere, compatible with DICOM-compliant and proprietary formats. It includes AI-powered data processing and visualization to extract insights about disease progression and treatment outcomes. It also supports global collaboration for participative research. The platform incorporates CE-marked AI algorithms for analyzing medical images in conditions like AMD, DR, DME, and Glaucoma.

How is RetinAI Discovery priced or packaged?

The provided evidence does not contain specific information about the pricing or packaging model for RetinAI Discovery. The homepage mentions a 'GET STARTED' button, but no pricing tiers, subscription plans, or cost details are listed.

What is RetinAI Discovery used for, and in what situations?

RetinAI Discovery is used to manage and access data, harmonize and analyze it at scale using AI, and enable collaborative research. It is used by healthcare professionals and pharmaceutical companies for clinical and research workflows in ophthalmology, such as accelerating drug development, building real-world evidence databases, and advancing studies in conditions like age-related macular degeneration (AMD) and diabetic retinopathy.

Who is RetinAI Discovery for?

RetinAI Discovery is designed for four main user groups: pharmaceutical and life sciences companies, clinics and hospitals, clinical and academic researchers, and academic AI researchers. The platform provides tools for data management, AI analysis, and collaboration tailored to these professionals in the ophthalmology field.

What is RetinAI Discovery?

RetinAI Discovery is an AI-powered healthcare platform for ophthalmology that enables medical professionals and pharmaceutical companies to manage clinical data, obtain AI-driven insights, and optimize clinical and research workflows. The homepage tagline describes it as a 'Transformative AI & data management platform to enable the right decisions sooner in Healthcare.'

Behind the lock

Unlock full RetinAI Discovery intelligence.

  • Backlink trajectoryThe figures above are the latest observation. The daily curve behind them holds 370.
  • AI referral detailHow much traffic assistants send.
  • Search structure and ranking depthOrganic against paid, brand against non-brand, and how many keywords rank in the top three against the long tail — which is what decides whether the demand is portable or tied to the name.
  • The rest of the marketPage through every leaderboard 100 rows at a time, put any five products side by side, and query the whole dataset over API / MCP.

Worldwide estimates · Data period 2026-05-01 → 2026-07-31. Figures are measured estimates intended for market research. Signals we have not measured for this domain are omitted, never estimated; a measured zero is still reported as zero. How this was measured